Author

Luisa Guidi 1

1 Complesso Integrato Columbus, Catholic University

CANCER AND INFLAMMATORY BOWEL DISEASE PHENOTYPE: A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY

Livia Biancone, Alessandro Armuzzi, Maria Lia Scribano, Renata D'Inca', Claudio Papi, Luisa Spina, Erika Angelucci, Carmelina Petruzziello, Luisa Guidi, Anna Kohn, Filippo Mocciaro, Patrizia Alvisi, Alessandra Ruffa, Rita Monterubbianesi, Walter Fries, Gabriele Riegler, Marco Daperno, Fabiana Castiglione, Giovanna Condino

ASSESSMENT OF LOSS OF RESPONSE TO INFLIXIMAB THERAPY IN INFLAMMATORY BOWEL DISEASES USING ANTIBODIES TO INFLIXIMAB AND TROUGH LEVELS.

Luisa Guidi, Manuela Marzo, Carla Felice, Daniela Pugliese, Gianluca Andrisani, Giammarco Mocci, Olga Maria Nardone, Gian Lodovico Rapaccini, Alfredo Papa, Alessandro Armuzzi, Gian Lodovico Rapaccini

CHARACTERIZATION OF INCIDENT CASES OF CANCER IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN A MULTICENTER CASE-CONTROL STUDY

Livia Biancone, Carmelina Petruzziello, Alessandro Armuzzi, Anna Kohn, Renata D'Incà, Claudio Papi, Luisa Spina, Luisa Guidi, Maria Lia Scribano, Emma Calabrese, Giovanna Condino, Sara Onali, Filippo Mocciaro, Rita Monterubbianesi, Patrizia Alvisi, Walter Fries, Gabriele Riegler, Giovanna Margagnoni, Roberto Di Mitri, Gi

LONG-TERM OUTCOMES OF ULCERATIVE COLITIS PATIENTS ON MONOTHERAPY MAINTENANCE TREATMENT WITH THIOPURINES: PRELIMINARY DATA

Daniela Pugliese, Pietro Manuel Ferraro, Annalisa Aratari, Giovanna Margagnoni, Rita Monterubbianesi, Carla Felice, Alfredo Papa, Luisa Guidi, Anna Kohn, Claudio Papi, Alessandro Armuzzi

Early Vedolizumab trough levels predict treatment persistence over the first year in inflammatory bowel disease

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Lorenzo Bertani, Francesco Costa, Giuseppe Privitera, Elisa Gremese, Barbara Tolusso, Clara Di Mario, Alfredo Papa, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

INCIDENT CANCER IN INFLAMMATORY BOWEL DISEASE: RISK FACTORS IN A  LONG TERM MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY AT 4 YEARS

Livia Biancone, Alessandro Armuzzi, Maria Lia Scribano, Renata D'Incà, Fabiana Castiglione, Erika Angelucci, Marco Daperno, Claudio Papi, Carmelina Petruzziello, Luisa Spina, Luisa Guidi, Anna Kohn, Filippo Mocciaro, Patrizia Alvisi, Alessandra Ruffa, Walter Fries, Gabriele Riegler, Emma Calabrese, Sara Renna, Roberto Di

INCIDENT CANCER IN INFLAMMATORY BOWEL DISEASE IN A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY

Livia Biancone, Alessandro Armuzzi, Maria Lia Scribano, Fabiana Castiglione, Renata D'Incà, Claudio Papi, Maurizio Vecchi, Gabriele Riegler, Filippo Mocciaro, Alessandra Ruffa, Benedetto Neri, Stefano Festa, Walter Fries, Patrizia Alvisi, Marco Daperno, Gianmichele Meucci, Luisa Guidi, Luisa Spina, Sara Renna, Emma Calab

INCIDENT CANCER IN INFLAMMATORY BOWEL DISEASE; CHARACTERIZATION AND RISK FACTORS IN A PROSPECTIVE MULTICENTER NESTED CASE-CONTROL IG-IBD STUDY AT 6 YEARS

Livia Biancone, Alessandro Armuzzi, Maria Lia Scribano, Fabiana Castiglione, Renata D'Incà, Marco Daperno, Claudio Papi, Maurizio Vecchi, Walter Fries, Gabriele Riegler, Patrizia Alvisi, Filippo Mocciaro, Alessandra Ruffa, Benedetto Neri, Stefano Festa, Anna Testa, Emma Calabrese, Roberto Di Mitri, Elena De Cristofaro, C

DEEP REMISSION IMPROVES CLINICAL OUTCOMES AFTER INFLIXIMAB DISCONTINUATION IN INFLAMMATORY BOWEL DISEASES

Carla Felice, Daniela Pugliese, Manuela Marzo, Gianluca Andrisani, Olga Maria Nardone, Alfredo Papa, Italo De Vitis, Gian Lodovico Rapaccini, Luisa Guidi, Alessandro Armuzzi

VEDOLIZUMAB TROUGH LEVELS PREDICT CLINICAL OUTCOMES IN INFLAMMATORY BOWEL DISEASE

Luisa Guidi, Daniela Pugliese, Tommaso Panici Tonucci, Barbara Tolusso, Carla Felice, Alfredo Papa, Italo De Vitis, Elisa Gremese, Antonio Gasbarrini, Gian Lodovico Rapaccini, Alessandro Armuzzi

Item 1 - 10 / 20
1
2